ABT vs. HLN: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ABT and HLN, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
ABT dominates in value with a market cap of 231.49 billion USD, eclipsing HLN’s 50.06 billion USD by roughly 4.62×.
ABT’s beta of 0.74 points to much larger expected swings compared to HLN’s calmer 0.20, suggesting both higher upside and downside potential.
HLN is an ADR, letting U.S. buyers tap its non-U.S. business directly, unlike ABT, which is purely domestic.
| Symbol | ABT | HLN |
|---|---|---|
| Company Name | Abbott Laboratories | Haleon plc |
| Country | US | GB |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Devices | Drug Manufacturers - Specialty & Generic |
| CEO | Mr. Robert B. Ford | Mr. Brian James McNamara |
| Price | 133.05 USD | 11.1 USD |
| Market Cap | 231.49 billion USD | 50.06 billion USD |
| Beta | 0.74 | 0.20 |
| Exchange | NYSE | NYSE |
| IPO Date | March 17, 1980 | July 25, 2022 |
| ADR | No | Yes |
Performance Comparison
This chart compares the performance of ABT and HLN over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ABT and HLN based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- HLN shows a negative forward PEG of -0.26, signaling expected earnings contraction, while ABT at 1.73 maintains analysts’ projections for stable or improved profits.
| Symbol | ABT | HLN |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 17.22 | 26.08 |
| Forward PEG Ratio (TTM) | 1.73 | -0.26 |
| Price-to-Sales Ratio (P/S, TTM) | 5.47 | 3.31 |
| Price-to-Book Ratio (P/B, TTM) | 2.48 | 2.33 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 34.77 | 0.00 |
| EV-to-EBITDA (TTM) | 22.97 | 19.43 |
| EV-to-Sales (TTM) | 5.63 | 4.01 |
| EV-to-Free Cash Flow (TTM) | 35.78 | 0.00 |
Dividend Comparison
Both ABT and HLN offer similar dividend yields (1.71% vs. 1.60%), indicating comparable approaches to balancing income and growth.
| Symbol | ABT | HLN |
|---|---|---|
| Dividend Yield (TTM) | 1.71% | 1.60% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ABT and HLN, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- HLN’s current ratio of 0.98 indicates its assets may not cover near-term debts, whereas ABT at 1.78 maintains healthy liquidity.
- HLN posts a quick ratio of 0.78, indicating limited coverage of short-term debts from its most liquid assets—while ABT at 1.27 enjoys stronger liquidity resilience.
| Symbol | ABT | HLN |
|---|---|---|
| Current Ratio (TTM) | 1.78 | 0.98 |
| Quick Ratio (TTM) | 1.27 | 0.78 |
| Debt-to-Equity Ratio (TTM) | 0.14 | 0.62 |
| Debt-to-Assets Ratio (TTM) | 0.16 | 0.29 |
| Interest Coverage Ratio (TTM) | 15.39 | 5.60 |